1225278-35-2

Basic information

• Product Name: BenzenaMine, 2,5-difluoro-4-[[2-(1-Methyl-1H-pyrazol-4-yl)-4-pyridinyl]oxy]-
• Synonyms: BenzenaMine, 2,5-difluoro-4-[[2-(1-Methyl-1H-pyrazol-4-yl)-4-pyridinyl]oxy]-;2,5-difluoro-4-(2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yloxy)aniline
• CAS NO: 1225278-35-2
• Molecular Formula: C₁₅H₁₂F₂N₄O
• Molecular Weight: 302.2787864
• Mol File: 1225278-35-2.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: BenzenaMine, 2,5-difluoro-4-[[2-(1-Methyl-1H-pyrazol-4-yl)-4-pyridinyl]oxy]-(CAS DataBase Reference)
• NIST Chemistry Reference: BenzenaMine, 2,5-difluoro-4-[[2-(1-Methyl-1H-pyrazol-4-yl)-4-pyridinyl]oxy]-(1225278-35-2)
• EPA Substance Registry System: BenzenaMine, 2,5-difluoro-4-[[2-(1-Methyl-1H-pyrazol-4-yl)-4-pyridinyl]oxy]-(1225278-35-2)

Safety Data

• Hazardous Substances Data: 1225278-35-2(Hazardous Substances Data)

Upstream product

• 17368-12-6 2-chloropyridin-4-ol 
• 1225278-64-7 2-chloro-4-(2 ,5-difluoro-4-nitrophenoxy)pyridine 
• 2105-61-5 1,2,4-trifluoro-5-nitrobenzene 
• 1225278-65-8 4-((2-chloropyridin-4-yl)oxy)-2,5-difluoroaniline 
• 761446-44-0 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole 

Downstream Products

• 1225278-79-4 methyl 1-((2,5-difluoro-4-(2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yloxy)phenyl)carbamoyl)cyclopropanecarboxylate 
• 1225278-13-6 1-(2,5-difluoro-4-(2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yloxy)phenyl)-3-(2-(4-fluorophenyl)acetyl)urea 

Relevant articles and documents

PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES

Compounds useful in the treatment of mammalian cancers and especially human cancers according to Formula I are disclosed. Formula (I). Pharmaceutical compositions and methods of treatment employing the compounds disclosed herein are also disclosed.

CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES

Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including, but not limited to, malignant melanomas, solid tumors, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, kidney cancers, hepatic cancers, cervical carcinomas, metastasis of primary tumor sites, myeloproliferative diseases, chronic myelogenous leukemia, leukemias, papillary thyroid carcinoma, non-small cell lung cancer, mesothelioma, hypereosinophilic syndrome, gastrointestinal stromal tumors, colonic cancers, ocular diseases characterized by hyperproliferation leading to blindness including various retinopathies, diabetic retinopathy, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, mastocytosis, mast cell leukemia, and diseases caused by PDGFR-α kinase, PDGFR-β kinase, c-KIT kinase, cFMS kinase, c-MET kinase, and oncogenic forms, aberrant fusion proteins and polymorphs of any of the foregoing kinases.